Trading Signals: ADAP Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Fri. May. 28, 2021)(Adaptimmune Therapeutics plc)
| ADAP latest price $6.3200 (2.27%) ($6.0800 - $6.4800) on Mon. Nov. 12, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.51% (three month average) | RSI | 42 | Latest Price | $6.3200(2.27%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADAP declines -2.4% a day on average for past five trading days. | Weekly Trend | ADAP advances 0.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADAP advance at 0% a week (0% probability) SMH(17%) GDXJ(12%) JETS(11%) FXI(9%) ICLN(9%) | Factors Impacting ADAP price | ADAP will decline at least -2.755% in a week (0% probabilities). XLP(-10%) XLV(-8%) VIXM(-8%) IFRA(-7%) VXX(-6%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.755% (StdDev 5.51%) | Hourly BBV | 0 () | Intraday Trend | 2.4% | | | |
|
1 - 5 Day Possible Target | $-49.93(-890.03%) | Resistance Level | $7.43 | 5 Day Moving Average | $6.47(-2.32%) | 10 Day Moving Average | $6.56(-3.66%) | 20 Day Moving Average | $7.43(-14.94%) | To recent high | -55.4% | To recent low | 6.4% | Market Cap | $977m | | | | Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom. |